Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pazopanib Maintenance for SCLC

Trial Profile

Phase II Study of Pazopanib Maintenance for SCLC

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 30 Jan 2018 Results assessing safety and efficacy published in the British Journal of Cancer
    • 18 Oct 2017 Primary endpoint (Progression-free survival) has been met, according to the results presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top